Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

• Status: Recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Aspirin; Ticagrelor

Criteria

Inclusion Criteria:

• Patients ≥ 19 years old

• Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for treating ACS

• Patients without significant clinical events such as MI, stent thrombosis or revascularization until 3 months after PCI

• Provision of informed consent

Exclusion Criteria:

• Age > 80 years

• Increased risk of bleeding, anemia, thrombocytopenia

• A need for oral anticoagulation therapy

• Pregnant women or women with potential childbearing

• Life expectancy < 1 year

• Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir)

• Patients who had history of intracranial hemorrhage

• Moderate to severe hepatic dysfunction

• Increased risk of bradycardia-related symptom (Guidance and reference)